Amy Baxter

2 days ago | pharmavoice.com | Amy Baxter

This audio is auto-generated. Please let us know if you have feedback. The FDA plans to roll out its new AI tool, called Elsa, “ahead of schedule and under budget,” according to Commissioner Dr. Marty Makary, who offered up the most information to date about the agency’s new tool and AI goals this week. But questions remain.

5 days ago | pharmavoice.com | Amy Baxter

This audio is auto-generated. Please let us know if you have feedback. The GLP-1 boom isn’t slowing down anytime soon. Prescriptions for overweight or obese adults jumped almost 587% from 2019 to 2024, Healthcare Dive reported, and there’s still a huge untapped patient population representing more market upside. As pharma’s pipeline explodes with more than 100 new drugs in various stages of development, one barrier to access has yet to be toppled.

1 week ago | sailingworld.com | Amy Baxter

Abie McLaughlin, age 38, had a breakout year in 2024, achieving a hat trick of North American championship wins in the J/88, Tartan 10 and S2 7.9 classes. Having quickly earned a reputation as a skilled and dedicated amateur sailor, she is now in demand as one of the best foredeck crews you’ve never heard of—until now. McLaughlin’s low-key personality has kept her under the radar.

1 week ago | pharmavoice.com | Amy Baxter

This audio is auto-generated. Please let us know if you have feedback. Following through on President Donald Trump’s “most favored nation” policy, the HHS is about to drop a drug pricing hammer on the pharma industry. But that doesn’t mean drugmakers will comply. The policy, issued by an executive order earlier this month in an attempt to bring U.S. drug prices in line with those paid in other countries, asks drugmakers to voluntarily lower their own price tags first.

2 weeks ago | pharmavoice.com | Amy Baxter

This audio is auto-generated. Please let us know if you have feedback. Welcome to First 90 Days, a series dedicated to examining how pharma executives and other leaders are planning for success in their new roles. Today, we’re speaking to Utpal Singh, chief scientific officer at Zealand Pharma, a peptide specialist that’s caught Big Pharma’s attention. Drugmakers looking for an edge in the booming obesity market aren’t just hunting for the next potential blockbuster.